Stock futures edged lower on Tuesday as sentiment took a hit after President-elect Donald Trump said he would raise tariffs ...

We recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to Analysts. In this article, we ...

Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...

On Tuesday, Arrowhead Pharmaceuticals Inc (ARWR) stock saw a modest uptick, ending the day at $21.05 which represents a slight increase of $2.26 or 12.03% from the prior close of $18.79. The stock ...

Strategic Sarepta partnership and FDA filing position Arrowhead for a transformative leap in RNAi therapeutics ...

RBC Capital analyst Luca Issi maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report) yesterday and set a price target of ...

U.S. stocks on Wednesday slipped, as investors digested a slight acceleration in the Federal Reserve's favorite inflation gauge. Here are some of Wednesday's biggest stock movers: Biggest stock ...

Needham lowered the firm’s price target on Sarepta (SRPT) to $202 from $205 and keeps a Buy rating on the shares. The deal with Arrowhead ...

Arrowhead Pharmaceuticals (ARWR) stock surges 21% in premarket after $825M licensing deal with Sarepta (SRPT) for rare ...

Check the time stamp on this data. Updated AI-Generated Signals for Arrowhead Pharmaceuticals Inc. (ARWR) available here: ...

Arrowhead Pharmaceuticals is a biotechnology company focused on developing RNA interference (RNAi) therapeutics. Their proprietary platform, Targeted RNAi Molecule (TRiM™), allows them to target and ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) is scheduled to be posting its quarterly earnings results after the ...